Evommune (NYSE:EVMN) Issues Quarterly Earnings Results, Misses Expectations By $0.61 EPS

Key Points

• Evommune missed expectations: the company reported an EPS loss of ($1.43) versus the consensus ($0.82), a shortfall of $0.61 for the quarter.
• Institutional and analyst support: multiple large funds (RA Capital, Pivotal bioVenture, JPMorgan, RTW, SymBiosis) opened sizable positions and analysts are largely positive, leaving a consensus "Moderate Buy" with an average price target of $49.67.
• Market reaction and valuation: shares rose to $27.06 on light volume, giving a market cap of about $853M and a negative P/E (-3.35), with a 52‑week range of $13.89–$33.20.

Evommune (NYSE:EVMN - Get Free Report) released its earnings results on Thursday. The company reported ($1.43) EPS for the quarter, missing the consensus estimate of ($0.82) by ($0.61), Zacks reports.

Evommune Stock Performance

EVMN stock traded up $1.97 during midday trading on Friday, reaching $27.06. 81,151 shares of the company's stock traded hands, compared to its average volume of 750,230. Evommune has a 52 week low of $13.89 and a 52 week high of $33.20. The firm has a market capitalization of $852.93 million and a P/E ratio of -3.35. The firm has a fifty day simple moving average of $21.87.

Institutional Investors Weigh In On Evommune

Institutional investors and hedge funds have recently made changes to their positions in the business. RA Capital Management L.P. acquired a new position in Evommune during the 4th quarter valued at about $59,214,000. Pivotal bioVenture Partners Investment Advisor LLC bought a new position in shares of Evommune in the fourth quarter valued at approximately $32,989,000. JPMorgan Chase & Co. purchased a new position in shares of Evommune during the fourth quarter valued at approximately $22,408,000. RTW Investments LP bought a new stake in Evommune during the fourth quarter worth $21,976,000. Finally, SymBiosis Capital Partners LLC purchased a new stake in Evommune in the 4th quarter valued at $21,927,000.

Analysts Set New Price Targets

Several analysts have recently commented on the stock. Leerink Partners assumed coverage on shares of Evommune in a research report on Monday, December 1st. They set an "outperform" rating and a $42.00 price objective for the company. The Goldman Sachs Group raised shares of Evommune to a "buy" rating in a research note on Wednesday, January 7th. Wall Street Zen upgraded shares of Evommune from a "sell" rating to a "hold" rating in a report on Sunday, December 14th. Zacks Research upgraded shares of Evommune to a "hold" rating in a report on Tuesday, December 2nd. Finally, Morgan Stanley reissued an "overweight" rating and set a $54.00 price objective on shares of Evommune in a research report on Wednesday, February 18th. Two research analysts have rated the stock with a Strong Buy rating, seven have issued a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the company's stock. Based on data from MarketBeat.com, Evommune presently has a consensus rating of "Moderate Buy" and an average price target of $49.67.

About Evommune

Evommune is a clinical-stage biotechnology company developing innovative therapies that target key drivers of chronic inflammatory diseases, with initial clinical development programs focusing on chronic spontaneous urticaria (“CSU”), atopic dermatitis (“AD”) and ulcerative colitis (“UC”). Chronic inflammation is a significant healthcare problem in the world, substantially impacting patients' quality of life and leading to life-threatening conditions. These conditions, if not prevented, ultimately lead to fatal diseases, such as cardiovascular diseases, diabetes and cancer, which contribute to three out of every five deaths worldwide and result in an estimated $90 billion of annual cost to the healthcare system in the United States.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.